ReviewMaterials today. Bio2026
Recent advances in self-assembled nanoplatforms for central nervous system disorders therapy: Design principles, multifunctional strategies, and therapeutic applications.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of central nervous system (CNS) disorders is increasing worldwide, while the development of CNS drugs remains extremely challenging due to high costs, long development cycles, and high failure rates. The CNS is highly protected by physiological barriers, particularly the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB), which severely restrict the entry of most therapeutic agents. Self-assembled nanocarriers (SA-NCs), characterized by relatively simple component composition and straightforward preparation processes, can be rationally engineered to bypass or penetrate these barriers, thereby enabling controlled and targeted drug delivery to the CNS. This review systematically summarizes recent advances in self-assembled nanoplatforms for CNS therapy. It first introduces the anatomical and functional barriers of the CNS along with current routes of administration. Subsequently, it explains the basic design principles and mechanisms of molecular self-assembly (SA), highlighting its unique advantages. The review then examines the multifunctional strategies of SA-NCs from the perspective of a spatiotemporal delivery process. Particular emphasis is placed on their ability to cross the BBB through membrane-translocating modifications for enhanced penetration, and subsequently accumulate at disease sites via functional modifications for targeted therapy. Finally, we discuss recent therapeutic applications in various CNS disorders and provide critical insights into current challenges in clinical translation, offering guidance for the future development of self-assembled nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.